Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 426-200-1 | CAS number: 172015-79-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- repeated dose toxicity: oral
- Adequacy of study:
- other information
Data source
Reference
- Reference Type:
- other: Body responsible for the test
- Title:
- Unnamed
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Annex V
- GLP compliance:
- yes
- Limit test:
- no
Test animals
- Species:
- other: Rat (Wistar)
Administration / exposure
- Route of administration:
- oral: unspecified
- Vehicle:
- corn oil
- Details on oral exposure:
- Method of administration:
Gavage - Duration of treatment / exposure:
- Test duration: 28 days
- Frequency of treatment:
- Dosing regime: 7 days/week
- No. of animals per sex per dose:
- Male: 5 animals at 0 mg/kg bw/day
Male: 5 animals at 1.5 mg/kg bw/day
Male: 5 animals at 15 mg/kg bw/day
Male: 5 animals at 150 mg/kg bw/day
Female: 5 animals at 0 mg/kg bw/day
Female: 5 animals at 1.5 mg/kg bw/day
Female: 5 animals at 15 mg/kg bw/day
Female: 5 animals at 150 mg/kg bw/day
Results and discussion
Results of examinations
- Details on results:
- Clinical observations:
All animals dosed with 150 mg/kg were killed on days 16 or
17 on humane grounds due to severe reductions in bodyweight
gain (Bodyweight 14-25% of control on days 16 or 17).
Signs of toxicity observed in this group were hunched
posture and piloerection. One male animal also showed tiptoe
gait. There were no treatment-related clinical effects in
animals in the 15 or 1.5 mg/kg/day dose groups.
Food consumption was also decreased in animals treated with
150 mg/kg/day (males - 15% and fenales -8%). There was no
significant difference in food consumption observed in
animals treated with 15 mg/kg/day or less.
No treatment-related effects or motor activity in the
functional observation bathing were observed.
Laboratory findings:
There were reductions observed in both males and females
dosed with 150 mg/kg/day in plasma glucose (45% and 32%)
total protein (25% and 27%) and albumin (22% and 28%). There
were increases in plasma bilirubin (200 and 850%), alkaline
phosphatase (51% and 224%), aspartate amino transferase
(133% and 177%) and creatine kinase (88% and 114%).
At 15 mg/kg/day there were reductions in plasma glucose (21%
and 17%), albumin (6% and 9%) and total protein (10% and
12%). There were increases in plasma bilirubin (70% and
167%), alkaline phosphate (10% and 50%) and apartate amino
transferase (52% and 177%). These changes were statistically
significant in both sexes.
There were increases in haemoglobin concentrations,
haematocrit, red cell count and total and differential white
cell counts, seen in both sexes at 150 mg/kg. These changes
were considered to be a secondary consequence of weight loss
and dehydration and not a direct toxicological effect.
There were no toxicologically significant haematological
effects observed in the 15 and 1.5 mg/kg dose group.
Effects in organs:
Minimal to slight adrenal corticol vacuolation and apoptosis
was noted in the 150 mg/kg treated males. Slight
hypertrophy/hyperplasia of the kidney collecting duct
epithelium, accompanied by slight or moderate tubular
dilation was observed in 3 males at this dose. Splenic red
pulp depleted of blood was also observed in 4 males. Minimal
to moderate panlobular hepatocellular degeneration was
observed in all animals at this dose, with minimal to
moderate biliary epithelial hyperplasia also being observed.
Minimal degenerative cardiomyopathy was also noted.
Microscopic changes: Minimal/slight biliary epithelial
hyperplasia was observed in all animals at 15 mg/kg. All
animals of this dose group also showed slight or moderate
panlobular hepatocellular degeneration. Slight to moderate
red pulp blood depletion was seen in 4 males at 15 mg/kg,
and minimal degenerative cardiomyopathy was present in 3
males at this dose. No changes were observed in the testis
at 15 or 150 mg/kg. No treatment-related liver changes were
seen in animals at 1.5 mg/kg.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 1.5 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
- Dose descriptor:
- NOEL
- Effect level:
- 1.5 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Classified as: Toxic
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
